A Patent Cliff and a Public Health Opportunity

The expiry of the patent for semaglutide in India marks a significant moment in the country’s pharmaceutical landscape, one that could reshape access to treatment for diabetes and obesity. With multiple domestic manufacturers preparing to introduce generic versions, the development is expected to bring down costs and widen availability.

Semaglutide, widely used in the management of type 2 diabetes and increasingly prescribed for weight loss, has until now remained out of reach for a large segment of patients due to its high price. The entry of generics is likely to change that equation, at least in part, by introducing competition and easing affordability.

This shift comes at a time when India is witnessing a steady rise in lifestyle-related conditions. Diabetes prevalence continues to climb, and concerns around obesity are no longer confined to urban centres alone. In this context, improved access to effective medication could have meaningful public health benefits.

Yet, the transition is not without its complexities. Questions around pricing strategies, regulatory oversight and quality assurance will need careful attention. The experience with other drugs suggests that while generics can reduce costs, the extent of that reduction depends on market dynamics and policy intervention.

There is also the broader issue of medical supervision. Drugs such as semaglutide are not a substitute for lifestyle changes, and their growing popularity for weight management raises concerns about misuse. Clear clinical guidelines and responsible prescribing practices will be essential.

The patent expiry presents an opportunity, but its impact will depend on how it is managed. Lower prices can expand access, but without a parallel emphasis on regulation and awareness, the benefits may remain uneven.